查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1541648

2024-2032 年按疫苗类型（减毒、灭活、基于亚单位、基于类毒素、基于DNA）、工作流程（下游、上游）、应用（人用、兽用）和地区分類的疫苗合约製造市场报告

Vaccine Contract Manufacturing Market Report by Vaccine Type (Attenuated, Inactivated, Subunit-based, Toxoid-based, DNA-based), Workflow (Downstream, Upstream), Application (Human Use, Veterinary), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球疫苗合约製造市场规模达28亿美元。

疫苗合约製造是指将疫苗的大规模生产外包给合约製造组织（CMO）。这些组织提供众多服务，包括製剂前工作、製剂开发、方法开发、稳定性研究、临床前活动、註册批次和商业生产。除此之外，他们还提供专业知识和创新技术来扩大製药公司的生产链。目前，由于开发成本降低和生产方案复杂，全球范围内对外包疫苗生产活动的需求正在增加。

疫苗接种在改善人类和兽医健康方面发挥关键作用。它减少了对抗生素的需求并预防疾病。人们对疫苗接种和许多相关益处（例如预防严重疾病和传染病）的认识不断提高，正在刺激对免疫计划和接种的需求。这与对生产资本要求的复杂性的了解相结合，导致领先的製药公司将疫苗生产外包。除此之外，资源匮乏国家缺乏疫苗生产设备和熟练劳动力也促进了全球疫苗合约製造市场的成长。此外，技术进步，包括引入 EB66 和 GPEx 等表达系统以及细胞培养基平台，正在支持市场成长。此外，许多国家的冠状病毒病 (COVID-19) 病例数量惊人增长，促使疫苗开发商与 CMO 签署外包协议。这为市场的成长创造了有利的前景。

本报告回答的关键问题：

  • 迄今为止，全球疫苗合约製造市场表现如何，未来几年将如何表现？
  • COVID-19 对全球疫苗合约製造市场有何影响？
  • 主要区域市场有哪些？
  • 根据疫苗类型，市场的细分情况如何？
  • 基于工作流程的市场区隔是怎样的？
  • 基于应用的市场区隔是什么？
  • 产业价值链的各个阶段是什么？
  • 该行业的关键驱动因素和挑战是什么？
  • 全球疫苗合约製造市场的结构如何？
  • 产业竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球疫苗合约製造市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依疫苗类型

  • 减弱的
    • 市场趋势
    • 市场预测
  • 灭活
    • 市场趋势
    • 市场预测
  • 基于亚基
    • 市场趋势
    • 市场预测
  • 基于类毒素
    • 市场趋势
    • 市场预测
  • 基于DNA
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依工作流程

  • 下游
    • 市场趋势
    • 关键环节
      • 填充和完成操作
      • 分析和品质控制研究
      • 包装
    • 市场预测
  • 上游
    • 市场趋势
    • 关键环节
      • 哺乳动物表达系统
      • 细菌表现系统
      • 酵母表现系统
      • 桿状病毒/昆虫表现系统
      • 其他的
    • 市场预测

第 8 章：市场区隔：按应用

  • 人类使用
    • 市场趋势
    • 市场预测
  • 兽医
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Ajinomoto Co. Inc.
    • Albany Molecular Research Inc
    • Catalent Inc
    • Cobra Biologics Limited (Charles River Laboratories International Inc.)
    • Cytovance Biologics Inc. (Hepalink USA Inc.)
    • Fujifilm Holdings Corporation
    • ICON plc
    • IDT Biologika GmbH
    • Lonza Group AG
    • Merck KGaA
    • Pharmaceutical Product Development LLC
    • PRA Health Sciences Inc.
Product Code: SR112024A3872

The global vaccine contract manufacturing market size reached US$ 2.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.1 Billion by 2032, exhibiting a growth rate (CAGR) of 8.8% during 2024-2032.

Vaccine contract manufacturing refers to the outsourcing of large-scale production of vaccines to contract manufacturing organizations (CMOs). These organizations offer numerous services, including pre-formulation work, formulation development, method development, stability studies, pre-clinical activities, registration batches and commercial manufacturing. Apart from this, they provide expertise and innovative technologies to expand the production chain of pharmaceutical companies. At present, the demand for outsourcing vaccine manufacturing activities is escalating worldwide on account of reduced development costs and complex production protocols.

Vaccination plays a pivotal role in improving human as well as veterinary health. It reduces the need for antibiotics and prevents diseases. The increasing awareness about vaccination and numerous associated benefits, such as protection from severe illnesses and infectious diseases, is catalyzing the demand for immunization programs and inoculations. This, in confluence with understanding the complexity of capital requirement for production, has led the leading pharmaceutical companies to outsource vaccine manufacturing. Apart from this, the lack of equipment and skilled labor for vaccine production in low-resource countries is also contributing to the global vaccine contract manufacturing market growth. Moreover, technological advancements, including the introduction of expression systems like the EB66 and GPEx and cell culture media platforms, are supporting the market growth. Furthermore, the alarmingly growing cases of coronavirus disease (COVID-19) in numerous countries have propelled the vaccine developers to sign outsourcing agreements with CMOs. This is creating a favorable outlook for the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global vaccine contract manufacturing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on vaccine type, workflow and application.

Breakup by Vaccine Type:

Attenuated

Inactivated

Subunit-based

Toxoid-based

DNA-based

Breakup by Workflow:

Downstream

Fill and Finish Operations

Analytical and QC Studies

Packaging

Upstream

Mammalian Expression Systems

Bacterial Expression Systems

Yeast Expression Systems

Baculovirus/Insect Expression Systems

Others

Breakup by Application:

Human Use

Veterinary

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Ajinomoto Co. Inc., Albany Molecular Research Inc, Catalent Inc, Cobra Biologics Limited (Charles River Laboratories International Inc.), Cytovance Biologics Inc. (Hepalink USA Inc.), Fujifilm Holdings Corporation, ICON plc, IDT Biologika GmbH, Lonza Group AG, Merck KGaA, Pharmaceutical Product Development LLC and PRA Health Sciences Inc.

Key Questions Answered in This Report:

  • How has the global vaccine contract manufacturing market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global vaccine contract manufacturing market?
  • What are the key regional markets?
  • What is the breakup of the market based on the vaccine type?
  • What is the breakup of the market based on the workflow?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global vaccine contract manufacturing market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Vaccine Contract Manufacturing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Attenuated
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Inactivated
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Subunit-based
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Toxoid-based
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 DNA-based
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Workflow

  • 7.1 Downstream
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Fill and Finish Operations
      • 7.1.2.2 Analytical and QC studies
      • 7.1.2.3 Packaging
    • 7.1.3 Market Forecast
  • 7.2 Upstream
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Mammalian Expression Systems
      • 7.2.2.2 Bacterial Expression Systems
      • 7.2.2.3 Yeast Expression Systems
      • 7.2.2.4 Baculovirus/Insect Expression Systems
      • 7.2.2.5 Others
    • 7.2.3 Market Forecast

8 Market Breakup by Application

  • 8.1 Human Use
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Veterinary
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Ajinomoto Co. Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Albany Molecular Research Inc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Catalent Inc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Cobra Biologics Limited (Charles River Laboratories International Inc.)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Cytovance Biologics Inc. (Hepalink USA Inc.)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Fujifilm Holdings Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 ICON plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 IDT Biologika GmbH
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Lonza Group AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck KGaA
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Pharmaceutical Product Development LLC
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 PRA Health Sciences Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials

List of Figures

  • Figure 1: Global: Vaccine Contract Manufacturing Market: Major Drivers and Challenges
  • Figure 2: Global: Vaccine Contract Manufacturing Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Vaccine Contract Manufacturing Market: Breakup by Vaccine Type (in %), 2023
  • Figure 5: Global: Vaccine Contract Manufacturing Market: Breakup by Workflow (in %), 2023
  • Figure 6: Global: Vaccine Contract Manufacturing Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Vaccine Contract Manufacturing Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Vaccine Contract Manufacturing (Attenuated) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Vaccine Contract Manufacturing (Attenuated) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Vaccine Contract Manufacturing (Inactivated) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Vaccine Contract Manufacturing (Inactivated) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Vaccine Contract Manufacturing (Subunit-based) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Vaccine Contract Manufacturing (Subunit-based) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Vaccine Contract Manufacturing (Toxoid-based) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Vaccine Contract Manufacturing (Toxoid-based) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Vaccine Contract Manufacturing (DNA-based) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Vaccine Contract Manufacturing (DNA-based) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Vaccine Contract Manufacturing (Downstream) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Vaccine Contract Manufacturing (Downstream) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Vaccine Contract Manufacturing (Upstream) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Vaccine Contract Manufacturing (Upstream) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Vaccine Contract Manufacturing (Human Use) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Vaccine Contract Manufacturing (Human Use) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Vaccine Contract Manufacturing (Veterinary) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Vaccine Contract Manufacturing (Veterinary) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Vaccine Contract Manufacturing Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Vaccine Contract Manufacturing Industry: SWOT Analysis
  • Figure 76: Global: Vaccine Contract Manufacturing Industry: Value Chain Analysis
  • Figure 77: Global: Vaccine Contract Manufacturing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Vaccine Contract Manufacturing Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Vaccine Type (in Million US$), 2024-2032
  • Table 3: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Workflow (in Million US$), 2024-2032
  • Table 4: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Vaccine Contract Manufacturing Market: Competitive Structure
  • Table 7: Global: Vaccine Contract Manufacturing Market: Key Players